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contained in the test sera. Nevertheless,
our findings do not allow to formally
exclude a direct impact of IVIg con-
centration on the performance of our
solid-phase assay. Furthermore, IVIg is a
heterogeneous product with various
effects and possible nonspecific bind-
ings. Disease severity scores, levels of
intercellular antibodies, and anti-Dsg-1
or -Dsg-3 IgG4 antibodies decreased
during IVIg therapy, showing both
laboratory and clinical improvement of
the disease (Table 1 and Figure 1).
Evidence for effects of disease anti-
bodies on apoptotic pathways have
been observed in pemphigus. Increased
expression of multiple caspases has
been detected in lesions of pemphigus
patients (Puviani et al., 2003; Wang
et al., 2004). In skin cultures, activation
of initiator caspases is seen after
treatment with pemphigus IgG (Arre-
dondo et al., 2005; Schmidt et al.,
2009). Furthermore, administration of
caspase inhibitors protects mice from
developing blisters induced by pemphi-
gus antibodies (Li et al., 2009),
which strongly suggests that caspase
activation is critically involved in the
formation of acantholysis. Livin and
XIAP have similar Baculoviral IAP
repeats inhibiting similar caspases and
both have a really interesting new gene
domain that has a role in protein
ubiquitination, which can induce in-
flammation and immunity. Survivin is
structurally different from other IAPs
because it lacks the really interesting
new gene domain. Survivin is known to
function as a major factor in cytokin-
esis, contributing to the resistance of
cancer cells to apoptosis (Richter and
Duckett, 2000).
In summary, we found that serum
levels of livin and XIAP increase mark-
edly with IVIg therapy, which is ac-
companied by a decrease in the levels
of pathogenic autoantibodies, as well as
disease severity. These results indicate
that increase in serum livin and XIAP
may be associated with clinical benefits
of IVIg. Although the sample size was
small, the striking results we report may
suggest performing functional studies
on the role of IAPs in the mechanism of
action of IVIg in preventing acantholy-
sis. In addition, evaluation of IAPs in
other IVIg-treated inflammatory disor-
ders is useful in further understanding
the mechanism of action of IVIg.
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TO THE EDITOR
The p16INK4a cyclin-dependent kinase
inhibitor acts as a negative regulator
of cyclin D-dependent kinases and is
a critical gatekeeper at the G1–S check-
point (Serrano et al., 1996). Accord-
ingly, p16INK4a is frequently inactivated
in human tumors, and deletions invol-
ving this locus occur frequently in
melanomas. Inherited mutations in the
p16INK4a gene are also associated with
melanoma susceptibility in 40% of multi-
ple-case melanoma families (Goldstein
et al., 2006). It is generally acknowl-
edged that the progressive and gradual
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loss of p16INK4a expression correlates
with the advancing stages of melanocytic
disease progression. Thus, benign nevi
show minimal loss of the p16INK4a gene,
whereas allelic loss of this locus is
common in dysplastic nevi, and in
primary and metastatic melanomas
(Talve et al., 1997; Sini et al., 2008).
Similarly, there is a progressive decrease
in the expression level of p16INK4a
protein from melanoma in situ to inva-
sive and metastatic melanomas (Keller-
Melchior et al., 1998; Sini et al., 2008).
The repression of p16INK4a expres-
sion is likely to commence earlier
than disease manifestation, occurring
during melanocytic proliferation, in
benign and atypical nevi. Initial reports
described qualitatively uniform immu-
nohistochemical labelling for p16INK4a
in nevi (Keller-Melchior et al., 1998),
but more recent studies have found
that the percentage of p16INK4a-positive
nevus cells and the intensity of stain-
ing were heterogeneous among nevi
(Michaloglou et al., 2005; Gray-Schopfer
et al., 2006). Reduced p16INK4a expres-
sion in nevi indicates that p16INK4a may
contribute to the clonal expansion of
nevus cells. This is supported by the
clinical observation that patients with
heterozygous p16INK4a mutations often
develop larger, more numerous, and
dysplastic nevi (Bishop et al., 2000). To
precisely examine the expression of
p16INK4a protein in nevi, we initially
determined the percentage of nevus
cells expressing detectable p16INK4a in
20 excised human nevi, comprising
15 compound nevi and 5 dysplastic nevi.
As shown in Figure 1, all nevi displayed
a heterogenous pattern of p16INK4a
immunopositivity, and although the
sample size was small we achieved
borderline statistical significance on com-
paring p16INK4a expression in compound
versus dysplastic nevi (Mann–Whitney
test; P¼0.053; Figure 1b).
Considering that normal melano-
cytes at the dermal–epidermal junction
have undetectable levels of p16INK4a
(data not shown; Michaloglou et al.,
2005), we sought to determine whether
expression of p16INK4a was actively lost
or simply not induced in some nevus
cells. During this investigation, we
discovered that the p16INK4a JC8 mouse
monoclonal antibody did not detect the
melanoma-associated p16INK4a R24P
variant in western and immunohisto-
chemical analysis (Figure 2a and b).
This antibody, which is raised against
full-length recombinant p16INK4a protein,
is frequently used for immunohistochem-
ical detection of p16INK4a in human
cancers (Redman et al., 2008). Using
melanocytic nevi from melanoma-prone
individuals from a single family (ID
31220) carrying a germline p16INK4a
mutation encoding the R24P variant
(Holland et al., 1995), we were able to
examine whether wild-type p16INK4a
expression was selectively lost in nevus
cells. In all, 11 nevi (8 compound nevi
and 3 dysplastic nevi) were derived from
five R24P carriers and 19 nevi (15
compound nevi and 4 dysplastic nevi)
were excised from age-matched melano-
ma-affected controls, with no known
family history of melanoma. The nevi
ranged in size from 2 to 22 mm for the
controls and from 3 to 20 mm for the
R24P carriers. The indication for excision
was clinical change within a clinically
dysplastic (atypical) nevus to exclude
melanoma (with low clinical suspicion
of malignancy) in the majority of cases.
We used dual immunofluorescence
with JC8 and C20 on paraffin-
embedded sections of nevi; the C20
antibody detects both wild-type and
mutant p16INK4a (Figure 2). R24P-positive
nevus cells expressing any combination
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Figure 1. p16INK4a expression in human melanocytic tumors. p16INK4a expression was determined using immunohistochemical analysis of 20 benign nevi.
(a) Representative examples of compound nevi stained with p16INK4a antibody (N20; Santa Cruz, Santa Cruz, CA) and positive cells detected using Permanent
Red (DAKO, Glostrup, Denmark). Bar¼ 50mm. (b) The results for 15 compound and 5 dysplastic nevi are represented graphically. Horizontal bars indicate
the median p16INK4a expression values.
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of R24P and wild-type p16INK4a stained
positively with C20, while the JC8
antibody stained positively only
in cells in which wild-type p16INK4a
expression was retained (see Figure 2b).
The distribution of p16INK4a was both
nuclear and cytoplasmic in all p16INK4a-
positive nevus samples. In R24P-positive-
only cells (JC8/C20þ ) the distribution
of mutant p16INK4a varied and showed
nuclear and cytoplasmic, predominantly
cytoplasmic, or predominantly nuclear
localization (data not shown). As expec-
ted, nearly all p16INK4a-positive control
nevus cells stained positively with both
the JC8 and C20 antibodies. In contrast, a
substantial proportion of nevus cells from
R24P carriers showed strong positivity
with only the C20 antibody (i.e. no JC8
positivity was seen) (Figure 2c) and
thus, these nevus cells were negative for
wild-type p16INK4a expression. As shown
in Figure 2d, there was a highly signi-
ficant difference between the control nevi
and R24P-positive nevi (Mann–Whitney
test; Po0.001); in the latter, wild-type
p16INK4a expression was selectively lost
in a subset (up to 31%) of nevus cells.
These data confirm that the loss of wild-
type p16INK4a expression commences
early in melanocyte proliferation, with
common benign nevi frequently contain-
ing cells with no p16INK4a.
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Figure 2. Selective loss of wild-type p16INK4a expression in human nevi. The activity of C20 and JC8 p16INK4a antibodies was examined using stable
melanoma clones with IPTG-inducible expression of wild-type p16INK4a, R24P, or both (McKenzie et al., 2010) in (a) western analysis or (b) dual fluorescence
staining of paraffin-embedded cell pellet sections derived from the indicated IPTG-induced melanoma clones. (c) Representative nevi from control individuals
or individuals carrying a germline R24P mutation were stained as indicated. Nuclei were stained with DAPI. Arrows indicate C20-positive/JC8-negative
nevus cells. Bar¼ 20mm. (d) Percent C20-positive/JC8-negative nevus cells (control nevi, n¼ 19; R24P nevi, n¼ 11). Horizontal bars indicate median
expression values; the control median was 0. AF-488, Alexa Fluor 488; AF-594; Alexa Fluor 594; DAPI, 40-6-diamidino-2-phenylindole; IPTG, isopropyl
b-D-1-thiogalactopyranoside.
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The mosaic pattern of p16INK4a ex-
pression in acquired nevi is reminiscent
of the heterogeneity of B-RAF mutations
found in human nevi (Lin et al., 2009).
It remains to be determined whether
the mutant B-RAF is coexpressed with
p16INK4a or if activated B-RAF and
loss of p16INK4a contribute separately
to the clonal expansion of melanocytes.
Alternatively, activated B-RAF and
p16INK4a deficiency may co-exist in
a small percentage of nevus cells to
enhance melanocyte proliferation and
drive neoplastic transformation. The
absence of a mutant-specific B-RAF
antibody has so far precluded the
execution of such an analysis. It is well
established that activated B-RAF can
promote nevus formation in murine and
fish melanoma models (Patton et al.,
2005; Goel et al., 2009), and the
arrested state of nevi does not appear
to require p16INK4a (Dhomen et al.,
2009). Nevertheless, the influence of
p16INK4a loss on the development of
B-RAFV600E-induced nevi needs to be
investigated in human melanocytic
tumors. This is particularly relevant as
p16INK4a loss regulates the penetrance
and latency of B-RAF-induced murine
melanomas (Dhomen et al., 2009).
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TO THE EDITOR
UVR is the main factor in skin cancer
(Bath-Hextall et al., 2007). Low-dose
UVB (280–320 nm) radiation is suffi-
cient for cutaneous photosynthesis of
previtamin D from 7-dehydrocholes-
terol (Tian and Holick, 1999). Some
epidemiologic studies suggest that a
poor vitamin D status increases the risk
for several cancers and autoimmune
diseases (Holick, 2008). Vitamin D
activity in peripheral tissues, such asAbbreviations: IVD, integrated density value; MED, minimal erythema dose; VDR, vitamin D receptor
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